CompetitionUS Vascepa continues to face rising generic competition & pricing pressure, which could intensify due to challenges in retaining some exclusive accounts.
Financial PerformanceTotal product revenue for 2Q24 was $47.5mn, down -27% y/y from 2Q23.
Market CoverageA large US national pharmacy benefit manager informed Amarin that it will no longer cover Vascepa as the exclusive icosapent ethyl product for its commercial national formularies, affecting a significant portion of the US Vascepa business.